The approval of the active substance napropamide is set to expire on 31 December 2023 in accordance with Commission Implementing Regulation (EU) 2018/670 [Commission Implementing Regulation (EU) 2018/670 of 30 April 2018 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances bromuconazole, buprofezin, haloxyfop-P and napropamide (OJ L 113, 3.5.2018, p. 1).].
Recital 5, Regulation (EU) 2023/2592
In forcesince 21 Nov 2023